LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will attend KeyBanc Capital Markets’ 25th Annual Technology Leadership Forum on Monday, August 5, 2024, in Vail, Colorado. In addition to hosting one-on-one meetings throughout the day, Mr. O’Connor will join a panel discussion entitled “AI and Digital Solutions for Drug Discovery” followed by a 25-minute Fireside Chat at 1:30 p.m. MDT (3:30 p.m. EDT).
The live audio webcast of Mr. O’Connor’s Fireside Chat can be accessed via this link and also on the Investors page of the Simulations Plus website where the replay will be available for 90 days following the event.
About Simulations Plus
With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | X | YouTube.
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2023 ESG update.
